Machine Learning to Predict Reentry Rates Using Hospital RWE
Machine learning, an advanced automated data analysis method, may predict 30-day hospital readmission rates, according to a report published [...]
PhRMA President Introduces Recipients of 2020 Challenge Award, Emphasizes Commitment to Patient Centricity
The PhRMA Foundation has expanded its vision of the value assessment framework to include health equity and patient centricity. PhRMA [...]
PharmacoEconomics Article Authors Discuss 8 Recommendations for CEAs in Diagnostic Assessments
An article published in PharmacoEconomics details eight recommendations regarding how cost-effectiveness analyses (CEAs) are used in diagnostics. The researchers call [...]
JAMA Network Open Article Highlights the Plight of the Uninsured as Drug Costs Soar
A recent article published in JAMA Network Open highlights one major healthcare spending trend: the uninsured. An increase in concentration [...]
Papa Raises $150 Million in Series D Funding, Seeks to Improve Health Equity
The startup Papa has raised $150 million in series D funding. The company aims to address loneliness by connecting seniors [...]
Panalgo and HealthEconomics.Com Host Webinar on Successful ICER Strategies
Panalgo and HealthEconomics.Com hosted a webinar detailing strategies that lead to successful evaluation by the Institute for Clinical and Economic [...]
Xcenda HEOR Experts Discuss ICER’s UPI Assessments
Xcenda’s Tasmina Hydery and Anne Loos shared their thoughts on the methodologies used by the Institute for Clinical and Economic [...]
HealthVerity’s IPGE RWD Platform Ensures Privacy
The HealthVerity Identity, Privacy, Governance and Exchange (IPGE) Platform offers useable real world data (RWD). The platform was created in [...]
RWD Advances Rare Disease R&D, Brings Hope to Patients
Patient registries are fast becoming a critical source of real world data (RWD), especially in rare disease research and development [...]
Leveraging RWD to Improve Outcomes for Patients With Mantle Cell Lymphoma
A collaboration between Janssen and Flatiron Health led to advancements in the research and care of patients with Mantle Cell [...]
[JAMA Article] New Oncology Drugs Command High Price Tags Despite Lack of Improved Survival
In an article published in JAMA Internal Medicine, researchers assessed the costs of 44 new oncology drugs. Surprisingly, they found [...]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and [...]
Flatiron ResearchX On-Demand Webinar on RWE in Regulatory Submissions
Flatiron ResearchX invited real world evidence (RWE) and pharma leaders to discuss how RWE impacts submissions to regulatory bodies. Available [...]
eBook on Rare Disease Therapies and Marketing Now Available
Rare Disease Advisor is offering a free eBook on rare disease (RD) trends and marketing efforts. The eBook details highly [...]
Amgen’s Patent Thicket Strategy Yields Billions in Drug Sales for TNF Inhibitor Enbrel
Amgen has employed a powerful strategy to maintain its monopoly on Enbrel, a drug that targets tumor necrosis factor (TNF) [...]
Veradigm Details the Power of Linked Healthcare Data in RWD Research
Sources of real world data (RWD) such as claims data, surveillance data gathered from disease registries, and electronic health record [...]
ICER Publishes Annual Hit List of 10 Drugs With Unsupported Price Hikes
The Institute for Clinical and Economic Review (ICER) has released its most recent report on Unsupported Price Increases (UPIs) for 2020. [...]
AllStripes Announces $50 Million in Series B Funding to Advance Rare Disease Research
AllStripes has raised $50 million in Series B Funding, led by Lux Capital. As a result, the organization has initiated [...]
Cerner’s First Chief Health Officer Seeks to Leverage EHR RWD to Predict Disease and Improve Patient Outcomes
According to Cerner, Nasim Afsar, MD, MBA, MHM will take on the position of Chief Health Officer in January 2022. [...]
Updated Promising Zone Design Improves Workflow and Clinical Trial Design for Biotechs
Promising Zone Design was first introduced a decade ago as a method to estimate sample size. The method is still [...]
RWE Expert and Economist Details Future Global Market Access and Pricing Trends
Economist Ulf Staginnus shared his thoughts on future trends for market access and drug pricing in a recent discussion with [...]
Will Mark Cuban’s PBM Deliver on Pricing Promises?
Mark Cuban’s new pharmacy benefit manager (PBM) venture and employer-run EmsanaRx are two of the latest players to enter the [...]
New Report Considers Use of Oncology RWE in Successful Submissions to the FDA
In a recent article published in Clinical Cancer Research, investigators analyzed successful submissions of oncology drugs to the Food and [...]
CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses
Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk [...]
Certara Leaders Discuss Leveraging RWD to Advance R&D and Meet Global Payers’ Needs
Certara’s Lee Stern and Shawn Bates shared their thoughts on how real world data (RWD) can be leveraged to meet [...]